Analysts' ratings for Eli Lilly and Co LLY over the last quarter vary from bullish to bearish, as provided by 17 analysts.
The table below summarizes their recent ratings, showcasing the evolving sentiments within the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 11 | 1 | 0 | 0 |
| Last 30D | 0 | 1 | 0 | 0 | 0 |
| 1M Ago | 2 | 1 | 0 | 0 | 0 |
| 2M Ago | 1 | 6 | 0 | 0 | 0 |
| 3M Ago | 2 | 3 | 1 | 0 | 0 |
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $865.18, a high estimate of $1001.00, and a low estimate of $723.00. This upward trend is apparent, with the current average reflecting a 5.99% increase from the previous average price target of $816.25.
Diving into Analyst Ratings: An In-Depth Exploration
The perception of Eli Lilly and Co by financial experts is analyzed through recent analyst actions. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $885.00 | $885.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $885.00 | $885.00 |
| Akash Tewari | Jefferies | Raises | Buy | $957.00 | $925.00 |
| David Toung | Argus Research | Raises | Buy | $840.00 | $770.00 |
| Evan Seigerman | BMO Capital | Raises | Outperform | $1001.00 | $900.00 |
| Chris Schott | JP Morgan | Raises | Overweight | $900.00 | $850.00 |
| Louise Chen | Cantor Fitzgerald | Raises | Overweight | $885.00 | $815.00 |
| Srikripa Devarakonda | Truist Securities | Raises | Buy | $892.00 | $850.00 |
| Louise Chen | Cantor Fitzgerald | Raises | Overweight | $885.00 | $815.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $815.00 | - |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $815.00 | - |
| Chris Shibutani | Goldman Sachs | Raises | Neutral | $723.00 | $650.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $815.00 | - |
| Andrew Baum | Citigroup | Raises | Buy | $895.00 | $675.00 |
| Louise Chen | Cantor Fitzgerald | Maintains | Overweight | $815.00 | - |
| Robyn Karnauskas | Truist Securities | Maintains | Buy | $850.00 | - |
| Chris Schott | JP Morgan | Raises | Overweight | $850.00 | $775.00 |
Key Insights:
- Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Eli Lilly and Co. This offers insight into analysts' perspectives on the current state of the company.
- Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Eli Lilly and Co compared to the broader market.
- Price Targets: Understanding forecasts, analysts offer estimates for Eli Lilly and Co's future value. Examining the current and prior targets provides insight into analysts' changing expectations.
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Eli Lilly and Co's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
Stay up to date on Eli Lilly and Co analyst ratings.
Unveiling the Story Behind Eli Lilly and Co
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.
Eli Lilly and Co: A Financial Overview
Market Capitalization Analysis: The company's market capitalization is above the industry average, indicating that it is relatively larger in size compared to peers. This may suggest a higher level of investor confidence and market recognition.
Revenue Growth: Eli Lilly and Co's remarkable performance in 3 months is evident. As of 31 March, 2024, the company achieved an impressive revenue growth rate of 25.98%. This signifies a substantial increase in the company's top-line earnings. As compared to competitors, the company surpassed expectations with a growth rate higher than the average among peers in the Health Care sector.
Net Margin: Eli Lilly and Co's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of 25.58%, the company showcases strong profitability and effective cost management.
Return on Equity (ROE): Eli Lilly and Co's financial strength is reflected in its exceptional ROE, which exceeds industry averages. With a remarkable ROE of 19.02%, the company showcases efficient use of equity capital and strong financial health.
Return on Assets (ROA): Eli Lilly and Co's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 3.51%, the company showcases efficient use of assets and strong financial health.
Debt Management: The company faces challenges in debt management with a debt-to-equity ratio higher than the industry average. With a ratio of 2.05, caution is advised due to increased financial risk.
How Are Analyst Ratings Determined?
Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish "analyst ratings" for stocks. Analysts typically rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
